| abstract |
Provided are an IL-21-anti-albumin single-domain antibody fusion protein pharmaceutical composition and use thereof. The pharmaceutical composition comprises an IL-21-anti-albumin single-domain antibody fusion protein and a buffer solution, may further comprise at least one stabilizer, and may optionally further comprise a surfactant. The IL-21-anti-albumin single-domain antibody fusion protein has high stability, and the single drug thereof and the use thereof in combination with the PD-1 monoclonal antibody exert superior anti-tumor activity. |